Product Name:
ERK1-pT202
Product Number:
ab-pk967
Target Full Name: Extracellular regulated protein-serine kinase 1 (p44 MAP kinase)
Target Alias: ERK-1; ERT2; Insulin-stimulated MAP2 kinase; Kinase ERK1; MAP kinase 1; MAPK 1; MAPK1; MAPK3; PRKM3; p44ERK1; p44MAPK; MGC20180; ENSG00000102882
Product Type Specific: ERK1 protein kinase phosphosite-specific antibody
Antibody Code: PK967
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: T202
Protein UniProt: P27361
Protein SigNET: ERK1
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human ERK1
Antibody Immunogen Sequence: TGFL(pT)E(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues T198 to E203.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.2 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Platypus | Chicken | Frog | Zebra fish | Honey bee | Nematode worm | Sea urchin.
Related Product 1: ERKSelectideA kinase substrate peptide (Cat. No.: PE-14CAA95)
Related Product 2: ERKSelectideB kinase substrate peptide (Cat. No.: PE-14CAB95)
Related Product 3: ERK1 T202+Y204 phosphorylation antibody (Cat. No.: AB-PK621)
Related Product 4: ERK1 Y204 phosphorylation antibody (Cat. No.: AB-PK864)
Related Product 5: ERK1 T207 phosphorylation antibody (Cat. No.: AB-PK865)
Related Product 6: ERK1 Y204+Y207 phosphorylation antibody (Cat. No.: AB-PK866)
Related Product 7: ERK1 S265 phosphorylation antibody (Cat. No.: AB-PK878)
Related Product 8: ERK1 S283 phosphorylation antibody (Cat. No.: AB-PK879)
Related Product 9: ERK1 T207 phosphorylation antibody (Cat. No.: AB-PK950)
Related Product 10: ERK2 T185+Y187 phosphorylation antibody (Cat. No.: AB-PK622)
Scientific Background: ERK1 (MAPK3) is a protein-serine/threonine kinase of the CMGC group and MAPK family. It functions as a central component of the MAP kinase intracellular signalling pathway. Phosphorylation at T202 and Y204 by MEK1 and MEK2 increases its phosphotransferase activity. Upon mitogenic stimulation, phosphorylation causes its translocation from the nucleus to the cytoplasm, inactivating its repressor function. Depending on the cellular context, this pathway is involved in the regulation of cell growth, survival, adhesion, or differentiation. More than 500 substrates have been identified for these MAP kinases. ERK1 activation leads to its translocation from the cytosol to the nucleus where it can target substrate proteins involved in cell cycle regulation; Cyclin D1, suppression of apoptosis; BCL2 and BAD, tumour supression; p53, cell migration; PAI-1, and MHCII mediated immune response; PPARg1. ERK1 appears to be a tumour requiring protein (TRP). The active form of the protein kinase normally acts to promote tumour cell proliferation. Dysfunction of MAPK3 expression and activity has been observed in a variety of cancers. Predominantly over-expression of MAPK3 or constitutive activation has been observed in cancer cell lines. Generally, activation of MAPK3 does not appear to be due to mutations in the protein itself but rather aberrant signalling in upstream factors including Raf, Ras and epidermal growth factor receptor. MAPK3 may also have a role in promoting metastasis in invasive tumours. Mutations resulting in the activation of the MAPK3 protein, but not necessary the over-expression of the MAPK3 protein, have been associated with tumorigenesis in several cancer types. This description may include information annotated by UniProt and/or Google AI.